Skip to main content

Pharmaceutical Stocks

Recent market-moving SEC filings and news across pharmaceutical companies, ranked by Wiseek's 1–10 importance score.

How Wiseek curates this list

Every item here is a high-importance (score ≥ 7) SEC filing or licensed news event for a pharmaceutical company, sourced from SEC EDGAR and licensed news wires and ranked by Wiseek's 1–10 importance score. The underlying source is linked from each article. See our methodology and editorial policy.

Related Healthcare industries

Biotech StocksMedical Device StocksHealth Tech StocksDiagnostics & Research StocksMedical Instrument StocksHealthcare Facility Stocks

See the full Healthcare sector feed.

ZeroStack Registers 54.6M Shares for Resale, Including 36.2M from MemeCore Deal
SEC FilingZSTK · Financing and Capital Events · 21h ago
FTC Challenges Amgen's Patent Play in Enbrel Antitrust Case
Dow Jones NewswiresAMGN · Legal and Risk Events · 1d ago
Iheezo Cuts Eye-Injection Discomfort 58% in Head-to-Head Study
BenzingaHROW · Product Development and Regulatory · 1d ago
Alvotech Inks $150M Licensing Deal with Lotus for Two Biosimilars
SEC FilingALVO · M&A and Partnerships · 1d ago
Alvotech Inks $150M Licensing Deal with Lotus for Two Biosimilars
GlobeNewswireALVO · M&A and Partnerships · 1d ago
CEO Sean Brynjelsen Sells $6.1M in Eton Stock Over Two Days
ProSEC FilingETON · Ownership and Investor Activity · 1d ago
Organigram Locks In Sanity Earnout at 85%, Unveils New Global Leadership
ProSEC FilingOGI · M&A and Partnerships · 1d ago
Alvotech Guides FY26 Revenue to $650M-$700M, Above Consensus
Dow Jones NewswiresALVO · Earnings and Guidance · 2d ago
Alvotech Reports H1 Loss, Secures $239.6M Capital, and Receives Positive FDA Facility Outcome
ProSEC FilingALVO · Financing and Capital Events · 2d ago
KALA BIO's Q2 10-Q Reveals Material Weakness, $7M Loan, and AI Platform License
ProSEC FilingKALA · Earnings and Guidance · 2d ago
Aurora Cannabis Buys UK Distributor and Pharmacy for £2.1M
SEC FilingACB · M&A and Partnerships · 2d ago
ZeroStack Buys $1B in MemeCore Tokens at 12x Premium, Appoints New President
ProSEC FilingZSTK · M&A and Partnerships · 3d ago
Sunshine Biopharma Wins Canadian Approval for Enalapril, Shipping by Year-End
ReutersSBFM · Product Development and Regulatory · 3d ago
Aurora Cannabis Urges Shareholders to Take No Action on Curaleaf's Hostile Bid
ProSEC FilingACB · M&A and Partnerships · 3d ago
Merck-Moderna mRNA Cancer Therapy Hits Phase 3 Endpoints in Melanoma
ProBusinessWireMRK · Product Development and Regulatory · 3d ago
IM Cannabis Plans 30:1 Reverse Split to Avoid Nasdaq Delisting
PR NewswireIMCC · Corporate Governance and Compliance · 3d ago
ZeroStack Completes Texas Continuance, Adopts New Charter with 1T Authorized Shares
SEC FilingZSTK · Corporate Governance and Compliance · 3d ago
Nasdaq Extends Akanda's Deadline to December 13 for Equity Compliance
SEC FilingAKAN · Legal and Risk Events · 4d ago
IM Cannabis Signs Definitive Agreement to Sell European Assets to CEO-Controlled Entity
ProSEC FilingIMCC · M&A and Partnerships · 5d ago
J&J's Monarch Quest 3 Robotic Bronchoscopy Platform Cleared by FDA
ReutersJNJ · Product Development and Regulatory · 5d ago
Enhertu Hits Primary Endpoint in First-Line HER2-Mutant Lung Cancer
ProSEC FilingAZN · Product Development and Regulatory · 5d ago
AstraZeneca Halts Phase III eVOLVE-Lung02 Trial of Volrustomig in Metastatic NSCLC
ProSEC FilingAZN · Product Development and Regulatory · 5d ago
Tagrisso + Orpathys Hits Both PFS and OS Endpoints in Phase III SAFFRON Trial
ProSEC FilingAZN · Product Development and Regulatory · 5d ago
Third FDA Form 483 in Two Months Hits Dr. Reddy's
ProSEC FilingRDY · Product Development and Regulatory · 5d ago
IM Cannabis Signs Definitive Deal to Sell European Assets, Boosting Equity by C$3M
ProPR NewswireIMCC · M&A and Partnerships · 5d ago
ORPATHYS plus TAGRISSO hits both PFS and OS endpoints in global Phase III SAFFRON trial
ProSEC FilingHCM · Product Development and Regulatory · 5d ago
Citius Oncology Files Prospectus Supplement: Board Expansion, Q3 Losses, Going Concern Warning
ProSEC FilingCTOR · Financing and Capital Events · 7d ago
Scilex Posts $115M Q2 Loss, Cash Dwindles to $0.6M, Going Concern Doubt Reiterated
ProSEC FilingSCLX · Earnings and Guidance · 7d ago
Citius Oncology's Q3 Loss, Going Concern Warning, and Nasdaq Delisting Risk
ProSEC FilingCTOR · Earnings and Guidance · 7d ago
Citius Oncology Q3 FY2026: $7.1M Revenue, 44 Institutions Ordering LYMPHIR
ProSEC FilingCTOR · Earnings and Guidance · 7d ago
FDA Approves Lantheus Brain-Imaging Agent for Alzheimer's Assessment
ProReutersLNTH · Product Development and Regulatory · 8d ago
Q2 2026 Results Extend Cash Runway to October 2027 as FDA Clears Lucid-MS Phase 2
SEC FilingQNTM · Earnings and Guidance · 8d ago
Quantum BioPharma Cuts Cash Burn 44%, Extends Runway to October 2027
GlobeNewswireQNTM · Earnings and Guidance · 8d ago
Oaktree Exits 5%+ Stake in Indivior, Sells 6.5M Shares
ProSEC FilingINDV · Ownership and Investor Activity · 8d ago
IM Cannabis Posts C$0.47 Q2 Loss Per Share Amid Going Concern Doubts
Dow Jones NewswiresIMCC · Earnings and Guidance · 8d ago
FDA Approves Bristol Myers' Iberdomide Combo for Multiple Myeloma
ProReutersBMY · Product Development and Regulatory · 8d ago
IM Cannabis Q2 Loss Widens to C$4.4M; Going Concern Doubts and Nasdaq Delisting Risk
ProSEC FilingIMCC · Earnings and Guidance · 8d ago
Biofrontera Q2 Revenue Jumps 33% but Going Concern Warning and ITC Setback Cloud Outlook
ProSEC FilingBFRI · Earnings and Guidance · 8d ago
Petros Pharmaceuticals Flags Going Concern, Material Weakness, and Massive Warrant Dilution
ProSEC FilingPTPI · Earnings and Guidance · 8d ago
Shuttle Pharma Sets Sept 3 Vote on 17.6M Share Issuance, 8M Equity Plan Increase, and Name Change to United Compute
ProSEC FilingSHPH · Corporate Governance and Compliance · 8d ago